Rapt Therapeutics winds down Phase 2 studies of lead candidate in wake of clinical holds

Rapt Ther­a­peu­tics said it will close and un­blind two mid-stage tri­als in atopic der­mati­tis and asth­ma af­ter they were put on clin­i­cal hold ear­li­er this year due to a case of liv­er fail­ure.

The com­pa­ny is now work­ing to clean the atopic der­mati­tis da­ta and an­tic­i­pates com­plet­ing its analy­sis in the third quar­ter. It is al­so con­tin­u­ing to in­ves­ti­gate the se­ri­ous ad­verse event that trig­gered the clin­i­cal holds.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.